Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors

Human Gene Therapy

Volumn 10, Issue 17, 1999, Pages 2727-2740

  Ji, Hongxiu ^a   Wang, Tian Li ^a   Chen, Chien Hung ^a,b   Pai, Sara I ^a   Hung, Chien Fu ^a   Lin, Ken Yu ^a   Kurman, Robert J ^a   Pardoll, Drew M ^a   Wu, T C ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; ENDOSOME; FEMALE; GENE GUN; GENE TARGETING; HELPER CELL; IMMUNE RESPONSE; INTRADERMAL DRUG ADMINISTRATION; LYSOSOME; MOUSE; NONHUMAN; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; TUMOR REGRESSION; VIRUS EXPRESSION; WART VIRUS;

ANIMALS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENDOSOMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PROTEIN SORTING SIGNALS; VACCINES, DNA;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MURINAE;

EID: 0033589811     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016474     Document Type: Article

References (42)

1. BOYLE, J.S., BRADY, J.L., and LEW, A.M. (1998). Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature (London) 392, 408-411.
2. CASARES, S., INABA, K., BRUMEANU, T.D., STEINMAN, R.M., and BONA, C.A. (1997). Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. Med. 186, 1481-1486.
3. CHEN, J.W., MURPHY, T.L., WILLINGHAM, M.C., PASTAN, I., and AUGUST, J.T. (1985). Identification of two lysosomal membrane glycoproteins. J. Cell Biol. 101, 85-95.
4. CLERICI, M., MEROLA, M., FERRARIO, E., TRABATTONI, D., VILLA, M.L., VENZON, D.J., SHEARER, G.M., DE PALO, G., and CLERICI, E. (1997). Cytokine production patterns in cervical intraepithelial neoplasia: Association with human papillomavirus infection limited to the cervix or involving other sites of the lower genital tract. J. Natl. Cancer Inst. 89, 245-250.
5. CONDON, C., WATKINS, S.C., CELLUZZI, C.M., THOMPSON, K., and FALO, L.D., Jr. (1996). DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. 2, 1122-1128.
6. DONNELLY, J.J., ULMER, J.B., and LIU, M.A. (1997). DNA vaccines. Life Sci. 60, 163-172. [Review].
7. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGEN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
8. FELTKAMP, M.C., SMITS, H.L., VIERBOOM, M.P., MINNAAR, R.P., DE DRIJFHOUT, J.W., TER MELIEF, C.J., and KAST, W.M. (1993). Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249.
9. FYNAN, E.F., WEBSTER, R.G., FULLER, D.H., HAYNES, J.R., SANTORO, J.C., and ROBINSON, H.L. (1993). DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U.S.A. 90, 11478-11482.
10. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M., and PARDOLL, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
11. GUARNIERI, F.G., ARTERBURN, L.M., PENNO, M.B., CHA, Y., and AUGUST, J.T. (1993). The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. J. Biol. Chem. 268, 1941-1946.
12. HADDAD, D., LILJEQVIST, S., STAHL, S., ANDERSSON, I., PERLMANN, P., BERZINS, K., and AHLBORG, N. (1997). Comparative study of DNA-based immunization vectors: Effect of secretion signals on the antibody responses in mice. FEMS Immunol. Med. Microbiol. 18, 193-202.
13. HECK, D.V., YEE, C.L., HOWLEY, P.M., and MUNGER, K. (1992). Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. U.S.A. 89, 4442-4446.
14. HUANG, A.Y., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
15. INCHAUSPE, G., VITVITSKI, L., MAJOR, M.E., JUNG, G., SPENGLER, U., MAISONNAS, M., and TREPO, C. (1997). Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: Comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol. 16, 185-195.
16. IWASAKI, A., TORRES, C.A.T., OHASHI, P.S., ROBINSON, H.L., and BARBER, B.H. (1997). The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159, 11-14.
17. JAKOB, T., WALKER, P.S., KRIEG, A.M., UDEY, M.C., and VOGEL, J.C. (1998). Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161, 3042-3049.
18. LEWIS, V., GREEN, S.A., MARSH, M., VIHKO, P., HELENIUS, A., and MELLMAN, I. (1985). Glycoproteins of the lysosomal membrane. J. Cell Biol. 100, 1839-1847.
19. LIN, K.-Y., GUARNIERI, F.G., STAVELEY-O'CARROLL, K.F., LEVITSKY, H.I., AUGUST, T., PARDOLL, D.M., and WU, T.-C. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26.
20. LINDSTEDT, R., LILJEDAHL, M., PELERAUX, A., PETERSON, P.A., and KARLSSON, L. (1995). The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 3, 561-572.
21. LUKAS, J., MULLER, H., BARTKOVA, J., SPITKOVSKY, D., KJERULFF, A.A., JANSEN, D.P., STRAUSS, M., and BARTEK, J. (1994). DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol. 125, 625-638.
22. MIYAHIRA, Y., MURATA, K., RODRIGUEZ, D., RODRIGUEZ, J.R., ESTEBAN, M., RODRIGUES, M.M., and ZAVALA, F. (1995). Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods 181, 45-54.
23. MURALI-KRISHNA, K., ALTMAN, J.D., SURESH, M., SOURDIVE, D.J., ZAJAC, A.J., MILLER, J.D., SLANSKY, J., and AHMED, R. (1998). Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 8, 177-187.
24. NAIR, S.K., BOCZKOWSKI, D., MORSE, M., CUMMING, R.I., LYERLY, H.K., and GILBOA, E. (1998). Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364-369.
25. NICHOLS, W.W., LEDWITH, B.J., MANAM, S.V., and TROILO, P.J. (1995). Potential DNA vaccine integration into host cell genome. Ann. N.Y. Acad. Sci. 772, 30-39.
26. OSTRAND-ROSENBERG, S. (1994). Tumor immunotherapy: The tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6, 722-727.
27. PARDOLL, D.M., and BECKERLEG, A.M. (1995). Exposing the immunology of naked DNA vaccines. Immunity 3, 165-169. [Review]
28. RODRIGUEZ, F., ZHANG, J., and WHITTON, J.L. (1997). DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71, 8497-8503.
29. ROWELL, J.F., RUFF, A.L., GUARNIERI, F.G., STAVELEY-O'CARROLL, K., LIN, X., TANG, J., AUGUST, J.T., and SILICIANO, R.F. (1995). Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J. Immunol. 155, 1818-1828.
30. RUFF, A.L., GUARNIERI, F.G., STAVELEY-O'CARROLL, K., SILICIANO, R.F., and AUGUST, J.T. (1997). The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J. Biol. Chem. 272, 8671-8678.
31. SANDERSON, S., FRAUWIRTH, K., and SHASTRI, N. (1995). Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 7217-7221.
32. SATO, Y., ROMAN, M., TIGHE, H., LEE, D., CORR, M., NGUYEN, M.D., SILVERMAN, G.J., LOTZ, M., CARSON, D.A., and RAZ, E. (1996). Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273, 352-354.
33. SHEN, Z., REZNIKOFF, G., DRANOFF, G., and ROCK, K.L. (1997). Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723-2730.
34. TINDLE, R.W., FERNANDO, G.J., STERLING, J.C., and FRAZER, I.H. (1991). A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. U.S.A. 88, 5887-5891.
35. TOBERY, T.W., and SILICIANO, R.F. (1997). Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185, 909-920.
36. TOPALIAN, S.L., RIVOLTINI, L., MANCINI, M., MARKUS, N.R., ROBBINS, P.F., KAWAKAMI, Y., and ROSENBERG, S.A. (1994). Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosine gene. Proc. Natl. Acad. Sci. U.S.A. 91, 9461-9465.
37. TORRES, C.A.T., IWASAKI, A., BARBER, B.H., and ROBINSON, H.L. (1997). Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 158, 4529-4532.
38. TSUKUI, T., HILDESHEIM, A., SCHIFFMAN, M.H., LUCCI, J.R., CONTOIS, D., LAWLER, P., RUSH, B.B., LORINCZ, A.T., CORRIGAN, A., BURK, R.D., QU, W., MARSHALL, M.A., MANN, D., CARRINGTON, M., CLERICI, M., SHEARER, G.M., CARBONE, D.P., SCOTT, D.R., HOUGHTEN, R.A., and BERZOFSKY, J.A. (1996). Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology. Cancer Res. 56, 3967-3974.
39. WILLIAMS, M.A., and FUKUDA, M. (1990). Accumulation of membrane glycoproteins in lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail. J. Cell Biol. 111, 955-966.
40. WU, T.C. (1994). Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol. 6, 746-754.
41. WU, T.-C. GUARNIERI, F.G., STAVELEY-O'CARROLL, K.F., VISCIDI, R.P., LEVITSKY, H.I., HEDRICK, L., CHO, K.R., AUGUST, T., and PARDOLL, D.M. (1995). Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc. Natl. Acad. Sci. U.S.A. 92, 11671-11675.
42. WU, Y., and KIPPS, T.J. (1997). Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol. 159, 6037-6043.